検索結果

R&D Pipeline | Research & Development | SENJU Pharmaceutica

PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) SJP-0132Dry eyeApproval（Japan） PranoprofeninflammationApplication under review (Vietnam) SJP-0132Dry eye

お知らせ | 千寿製薬株式会社

2026年04月06日 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） 2025年12月22日 Obtained manufacturing and marketing approval in Ja...

オロパタジン点眼液0.1％「センジュ」

た12） 。 19. 有効成分に関する理化学的知見 一般名：オロパタジン塩酸塩 （Olopatadine Hydrochloride） 〔JAN〕 化学名： ｛11-[ （1 ） -3- （Dimethylamino） propylidene]-6, 11- dihydrodibenzo[b, e]oxepin-2-yl}acetic acid monohydrochloride 構造式： 分子...

Data And Statistics | About Senju | SENJU Pharmaceutical

6% 2.2 4.7% 2.6 5.5% 2.8 5.7% Overseas Business 5.1 12.5% 6.4 15.8% 8.1 17.5% 9.9 20.3% 10.9 22.4% Others 0.5 1.2% 2.0 5.0% 2.0 4.4% 2.2 4.7% 1.4 2.9% ＊A new accounting standard for revenue recognitio...

harmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction b...